Last mentioned: Mar 19, 2026
Healthy China 2030 Deadline
Target date for achieving major healthcare and biotech self-sufficiency milestones.
Strategic Target
Deadline for China to become the primary global exporter of medical technology standards.
Official Launch
President Xi Jinping unveils the 15th FYP at the National People's Congress.
Leadership Mandate
New policy shift explicitly targets global leadership over 'catching up' with Western tech.
15th FYP Drafting
Central Committee reviews the initial draft of the 2026-2030 strategic plan.
Patent Milestone
China surpasses the US in total international patent filings for CRISPR and AI-drug discovery.
14th FYP Implementation
Focus on 'Dual Circulation' and initial biotech innovation pivot.
14th Five-Year Plan
China emphasizes 'self-reliance' and domestic technology loops.
President Xi Jinping’s 15th Five-Year Plan (2026-2030) positions biotechnology as a cornerstone of "New Quality Productive Forces," prioritizing domestic innovation and supply chain self-sufficiency. This strategic shift aims to decouple China’s life sciences sector from Western dependencies while accelerating the commercialization of cell and gene therapies.
China’s latest strategic roadmap shifts from a 'catch-up' posture to a mandate for global leadership in frontier technologies. This pivot places biotechnology and genomic medicine at the center of national security and economic growth, challenging decades of U.S. dominance in drug innovation.
This page surfaces every story mentioning National Medical Products Administration (NMPA) across our biotech coverage. We track each entity's appearance over time so readers can trace how the narrative evolves — which developments are isolated incidents, which build into longer arcs, and which reframe how operators in the space think about the entity. Story selection uses the same multi-source verification gate applied across the rest of our coverage.
Read our editorial methodology for how we identify, deduplicate, and score entity references. Our glossary defines the technical terms used across stories on this page, and our trends index contextualizes individual developments against the longer-running biotech beat. Cross-entity comparisons live on our compare view.
| What you see | What it tells you |
|---|---|
| Story count | Number of distinct stories where National Medical Products Administration (NMPA) was a primary or referenced actor. |
| Recency clustering | Whether mentions are concentrated in a recent window (a news cycle) or distributed (a sustained arc). |
| Sentiment distribution | Aggregate sentiment of the stories mentioning this entity, weighted by impact score. |
| Cross-niche links | When the same entity surfaces in our sibling networks, we link to those views to enrich context. |